The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Agios Pharmaceuticals, Inc. | COM | 00847X104 | 343,973 | 3,070,090 | SH | DFND | 3,070,090 | 0 | 0 | ||
| bluebird bio, Inc. | COM | 09609G100 | 111,445 | 1,215,054 | SH | DFND | 1,215,054 | 0 | 0 | ||
| Eleven Biotherapeutics, Inc. | COM | 286221106 | 57,518 | 4,841,591 | SH | DFND | 4,841,591 | 0 | 0 | ||
| Foundation Medicine, Inc. | COM | 350465100 | 109,483 | 4,927,234 | SH | DFND | 4,927,234 | 0 | 0 | ||
| Sage Therapeutics, Inc. | COM | 78667J108 | 427,525 | 11,681,008 | SH | DFND | 11,681,008 | 0 | 0 | ||
| Zafgen Inc. | COM | 98885E103 | 172,767 | 5,602,045 | SH | DFND | 5,602,045 | 0 | 0 | ||